1. Home
  2. IDYA vs UE Comparison

IDYA vs UE Comparison

Compare IDYA & UE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IDYA
  • UE
  • Stock Information
  • Founded
  • IDYA 2015
  • UE 2014
  • Country
  • IDYA United States
  • UE United States
  • Employees
  • IDYA N/A
  • UE N/A
  • Industry
  • IDYA Biotechnology: Pharmaceutical Preparations
  • UE Real Estate
  • Sector
  • IDYA Health Care
  • UE Finance
  • Exchange
  • IDYA Nasdaq
  • UE Nasdaq
  • Market Cap
  • IDYA 2.0B
  • UE 2.2B
  • IPO Year
  • IDYA 2019
  • UE N/A
  • Fundamental
  • Price
  • IDYA $21.67
  • UE $18.59
  • Analyst Decision
  • IDYA Strong Buy
  • UE Hold
  • Analyst Count
  • IDYA 12
  • UE 1
  • Target Price
  • IDYA $54.27
  • UE $22.00
  • AVG Volume (30 Days)
  • IDYA 1.2M
  • UE 961.5K
  • Earning Date
  • IDYA 08-05-2025
  • UE 07-30-2025
  • Dividend Yield
  • IDYA N/A
  • UE 4.09%
  • EPS Growth
  • IDYA N/A
  • UE N/A
  • EPS
  • IDYA N/A
  • UE 0.63
  • Revenue
  • IDYA $7,000,000.00
  • UE $453,505,000.00
  • Revenue This Year
  • IDYA $101.20
  • UE $6.42
  • Revenue Next Year
  • IDYA $286.70
  • UE $4.60
  • P/E Ratio
  • IDYA N/A
  • UE $29.31
  • Revenue Growth
  • IDYA N/A
  • UE 8.73
  • 52 Week Low
  • IDYA $13.45
  • UE $15.66
  • 52 Week High
  • IDYA $44.42
  • UE $23.85
  • Technical
  • Relative Strength Index (RSI)
  • IDYA 58.21
  • UE 52.58
  • Support Level
  • IDYA $21.09
  • UE $18.22
  • Resistance Level
  • IDYA $22.50
  • UE $18.92
  • Average True Range (ATR)
  • IDYA 0.97
  • UE 0.37
  • MACD
  • IDYA -0.04
  • UE 0.01
  • Stochastic Oscillator
  • IDYA 56.44
  • UE 51.25

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

About UE Urban Edge Properties of Beneficial Interest

Urban Edge Properties is a real estate investment trust principally focused on the management and development of retail real estate properties in urban communities in the U.S. Having originally been created to hold the majority of Vornado Realty Trust's shopping center businesses, Urban Edge's asset portfolio is mostly composed of shopping centers and malls in terms of total square footage. The company's holdings include necessity and convenience-oriented retailers, such as department stores, grocers, health clubs, and restaurants. Urban Edge's properties are mainly located in the New York City metropolitan region and within the DC to Boston corridor. The company generates nearly all of its revenue through the collection of rent from a large number of tenants.

Share on Social Networks: